In:
Russian Journal of Allergy, Farmarus Print Media, Vol. 8, No. 5 ( 2011-10-15), p. 37-44
Abstract:
Abstract: 15 kids (1-3 years old) with recurrent infections received therapy with Broncho-munal (1 capsule/day)
from the day 1 till the day 30 after measles vaccination. The control group of 29 kids of the same age did not receive any immunomodulatory therapy after the vaccination. 12 out of 15 (80%) kids in the Broncho-munal
group developed no complications after the vaccination compared with 20 out of 29 kids (68,9%) in the control group. The frequency of intercurrent infections was 3,5 times lower in the Broncho-munal group. The kids in
the Broncho-munal group developed neither lymphopenia nor leukopenia. They had increased counts of CD25+ and CD20+ cells by the day 30 after the vaccination, prolonged production of the specific antibodies as well as
higher geometric mean titers of the anti-measles antibodies on the day 45 after the vaccination. Taken together these observations suggest that Broncho-munal protected from the transitory immunosuppressive effects of
the vaccination.
Type of Medium:
Online Resource
ISSN:
2686-682X
,
1810-8830
Language:
Unknown
Publisher:
Farmarus Print Media
Publication Date:
2011
